MONTREAL, QUEBEC--(Marketwire - January 17, 2008) - Thallion Pharmaceuticals Inc. (TSX: TLN) today announced the resolution of the outstanding dispute with its licensor of CAP-232, Expergen Drug Development GmbH of Austria. A settlement agreement was signed by both parties and, subject to certain normal closing conditions, is effective immediately.
